Drug intelligence / Profile preview

nortriptyline

Development stage: Approved
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Nortriptyline is a tricyclic antidepressant (TCA) used primarily to treat depression. It works by inhibiting the reuptake of norepinephrine and serotonin in adrenergic and serotonergic neurons, thereby increasing the levels of these neurotransmitters in the brain and helping to restore mental balance. Nortriptyline is also prescribed off-label for conditions such as neuropathic pain (including post-herpetic neuralgia), panic disorders, and as an aid for smoking cessation. The drug is available in oral capsule and liquid forms[1][2][4][5][6][8].

Brand names: PamelorAventyl
Other names: nortriptylineAventyl HCl

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on nortriptyline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nortriptyline.

Explore the full profile